Drug Trial Radar · NCT07834515
Phase 1b Clinical Study in Patients With Active Ulcerative Colitis
Last checked: Nov 20, 2026Latest source record: Sep 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
24
Planned (sponsor's estimate)
Start
Sep 16, 2026
Primary completion
Jul 29, 2027
Study completion Aug 29, 2027
Sponsor
- Lead sponsor
- Thetis Pharmaceuticals LLCIndustry
- Sponsor type
- Industry
- First posted
- Sep 22, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Purpose of study is to evaluate the safety, tolerability, pharmacokinetics of TP317 vs. placebo in adults with active ulcerative colitis. Participants will be randomly assigned to receive either daily oral tablets (8 tablets) of TP317 (80 mg) or an identical placebo pill. Study will include 2 colonoscopies, daily dosing (including at home and in clinic), safety assessments, diary and questionnaire completion and 5 in clinic visits.
Conditions
- Ulcerative Colitis (UC)
Interventions
TP317Drug
8 tablets (80 mg) of TP317 oral tablets, taken once daily under fasted conditions for a total duration of 12 weeks.
Matching placeboDrug
Matching oral tablet containing no active ingredients, taken once daily for 12 weeks to maintain blinding.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety of TP317Time frame: Collected from baseline through Week 12
- Safety of TP317Time frame: Baseline through Week 12
- Safety of TP317Time frame: Baseline through Week 12
- Safety of TP317Time frame: Baseline to Week 12
- Pharmacokinetics of TP317Time frame: Baseline through Week 12
- Pharmacokinetics of TP317Time frame: Baseline through Week 12
- Pharmacokinetics of TP317Time frame: Baseline through Week 12
- Pharmacokinetics of TP317Time frame: Baseline through Week 12
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.